Vasopressin and platelets: A concise review

Platelets

Volumn 8, Issue 1, 1997, Pages 15-22

  Wun, Ted ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; NEUROHYPOPHYSIS HORMONE; PEPTIDE HORMONE; VASOPRESSIN;

ANTIDIURESIS; CHEMISTRY; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS; HUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

EID: 0030970208     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537109777492     Document Type: Review

References (41)

1. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. The Pharmacologic Basis of Therapeutics. New York: McGraw-Hill, 1996: 715.
2. Manning M, Bankowski K, Sawyer WH. Selective agonists and antagonists of vasopressin. In: Gash DM, Boer GJ, eds. Vasopressin: Principles and Properties. New York: Plenum Press, 1987: 335.
3. Grant PJ, Davies JA, Tate GM, Boothby M, Prentice CRM. Effects of physiological concentrations of vasopressin on haemostatic function in man. Clin Sci 1985; 69: 471-6.
4. Cowley AWJr, Liard J, In: Gash DM, Boer GJ, eds. Vasopressin: Principles and Properties. New York: Plenum Press, 1987: 389.
5. Brooks DP, Share L, Crofton JT. Vasopressin: the control of its release and cardiovascular actions. In: Schrier RW, ed. Vasopressin. New York: Raven Press, 1985: 69.
6. Burns SM, Martin M, Merrill P, Luer J, Stone DD. Evaluation and revision of a vasopressin/nitroglycerin protocol for use in variceal bleeding. Am J Critical Care 1993; 2: 202-7.
7. Goff JS. Gastroesophageal varices: pathogenesis and therapy of acute bleeding. Gastroenterol Clin N Am 1993; 22: 779-801.
8. Ready JB, Robertson AD, Rector WGJr. Effects of vasopressin on portal pressure during hemorrhage from esophageal varices. Gastroenterology 1991; 100: 1411-5.
9. Thibonnier M, Roberts JM. Characterization of human platelet vasopressin receptors. J Clin Investig 1985; 76: 1857-64.
10. Manning M, Sawyer WH. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med 1989; 114: 617-32.
11. Siess W, Stifel M, Binder H, Weber PC. Activation of VI-receptors by vasopressin stimulates inositol phospholipid hydrolysis and arachidonate metabolism in human platelets. Biochem J 1986; 233: 83-91.
12. Nussey SS, Bevan DH, Ang VTY, Jenkins JS. Effects of arginine vasopressin (AVP) infusions on circulating concentrations of platelet AVP, Factor VIII:C, and von Willebrand factor. Thromb Haemost 1986; 55: 34-6.
13. 125I-8-L-arginine vasopressin binding to human mononuclear phagocytes. J Clin Investig 1981; 68: 374-81.
14. Hashemi S, Palmer DS, Aye MT, Ganz PR. Platelet activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. J Cell Physiol 1993; 154: 496-505.
15. Barnhart MI, Chen S, Lusher JM, DDAVP: does the drug have a direct effect on the vessel wall. Thromb Res 1983; 31: 239-53.
16. Haslam RJ, Rosson GM. Aggregation of human platelets by vasopressin. Am J Physiol 1972; 223: 958-67.
17. Lachant NA, Smith MR, Xie Z, Romani WR. Heterogeneity of the aggregation response of human platelets to arginine vasopressin. Am J Hematol 1995; 49: 56-66.
18. Thibonnier M, Hinko A, Pearlmutter AF. The human platelet vasopressin receptor and its intracellular messengers: key role of divalent cations. J Cardiovasc Pharmacol 1987; 10: 24-29.
19. Thomas ME, Osmani AH, Scrutton MC. Some properties of the human platelet vasopressin receptor. Thromb Res 1983; 32: 557-66.
20. Bichet DG, Arthus MF, Barjon JN, Lonergan M, Kortas C. Human platelet fraction arginine-vasopressin: potential physiologic role. J Clin Investis 1987; 79: 881-7.
21. Nussey SS, Ang VTY, Bevan DH, Jenkins JS. Human platelet arginine vasopressin. Clin Endocrinol 1986; 24: 427-33.
22. Wun T, Paglieroni TG, Lachant NA. Physiologic concentrations of arginine vasopressin activate human platelets in vitro. Brit J Haematol 1996; 92: 968-72.
23. Moffat EH, Giddings JC, Bloom AL. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities. Br J Haematol 1984; 57: 651-62.
24. Salzman EW, Weinstein MJ, Reilly D, Ware JA. Adventures in hemostasis-Desmopressin in cardiac surgery. Arch Surg 1993; 128: 212-7.
25. Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 1449-55.
26. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990; 33: 39-45.
27. Rodghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 1989; 74: 1997-2000.
28. Cattaneo M, Moia M, Della Valle P, Castellana P, Mannucci PM. DDAVP shortens the prolonged bleeding time of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. Blood 1989; 74: 1972-5.
29. Hackmann T, Gascoyne RD, Naiman SC, Growe GH, Burchill LD, Jamieson WRE, Sheps SB, Schechter MT, Townsend GE. A trial of desmopressin (I-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. New Engl J Med 1989; 321: 437-43.
30. Salzman EW, Weinstein MJ, Weintraub RM, Ware JA, Thurer RL, Robertson L, Donovan A, Gaffney T, Bertele V, Troll J, Smith M, Chute LE. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: a double-blind randomized trial. New Engl J Med 1986; 314: 402-6.
31. Yang X, Disa J, Rao AK. Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on human platelets. Thromb Res 1990; 59: 809-18.
32. + exchange. Thromb Haemorr Dis 1993; 8: 9-14.
33. Sloand EM, Alyono D, Klein HM, Chang P, Yu M, Lightfoot FG, Kessler C. 1-deamino-8-D-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass. Am J Hematol 1994; 46: 199-207.
34. Wun T, Paglieroni TG, Lachant NA. Desmopressin stimulates the expression of P-selectin on human platelets in vitro. J Lab Clin Med 1995; 125: 401-9.
35. Launay JM, Vittet D, Vidaud M, Rondot A, Mathieu MN. Lalau-Keraly C, Cantau B, Chevillard C. V1a-vasopressin specific receptors on human platelets: potentiation by ADP and epinephrine and evidence for homologous down-regulation. Thromb Res 1987; 45: 323-31.
36. Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, Kubes P. Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood 1995; 86: 2760-6.
37. Tsai H, Sussman II, Nagel RL, Kaul DK. Desmopressin induces adhesion of normal human erythrocytes to the endothelial surface of a perfused microvascular preparation. Blood 1990; 75: 261-5.
38. Horstman LL, Valle-Riestra BJ, Jy W, Wang F, Mao W, Ahn YS. Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity. Thromb Res 1995; 79: 163-74.
39. Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. L Lab Clin Med 1992; 119: 334-45.
40. Soederlund C. Terlipressinb (glypressin) in the treatment of bleeding esophageal varices. State of the art. Reg Pep 1993; 45: 299-302.
41. Lachant NA, Smith MR. V1 neurohypophyseal peptide-agonist induced platelet aggregation: effect of vasopressin analogues. Clin Res 1992; 40: 378A.